Breaking new ground in protein detection, quantification and purification
Since 1983, PROGEN has been an established manufacturer and supplier of premium antibodies, in vitro diagnostics, and reagents for the global life science research community. PROGEN’s antibodies are among the most published antibodies in biomedical and cell biology literature. Based on its core competency in immunochemistry, the company now intends to become a driver of innovative antibody technologies for protein detection, quantification, and purification.
For the detection of cellular targets such as signaling molecules or biomarkers in cell biology research and routine diagnostics, PROGEN is developing new antibody and assay formats. In this context, the company will establish a novel test system for the detection of rheumatoid arthritis based on microarray-identified peptide biomarkers as part of a BMBF-funded project.
Furthermore, alternative immunochemical methods are explored to facilitate and accelerate protein quantification for medical applications, e.g. for the determination of virus titers in gene therapy.
Utilizing the resources of PROGEN’s 500+ premium antibodies, the company plans to establish a protein purification portfolio for the research market. These products will encompass new technologies for improved extraction, concentration and purification of proteins in a wide range of applications.
In summary, PROGEN is advancing its portfolio to include improved and convenient immunochemical tools for protein detection, quantification and purification. The company is therefore actively looking for collaborators in academia and industry for flexible co-development. If you are interested please contact Dr. Sven Kuhlendahl, General Manager, at firstname.lastname@example.org or visit www.progen.com for further information.